source
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.BioPharma Dive · 2mo ago↗ source
- Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…Endpoints · 2mo ago↗ source
- #ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T updateCHICAGO — Eli Lilly in April signed an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...